Navigation Links
Acura and King Receive FDA Complete Response Letter Regarding Acurox(R)
Date:7/2/2009

erning the Complete Response Letter and the Companies' expectations regarding any meeting with the FDA to discuss the Complete Response Letter. Acura Pharmaceuticals, Inc. and King Pharmaceuticals, Inc. disclaim any intent or obligation to update these forward-looking statements, and claim the protection of the Safe Harbor for forward-looking statements contained in the Act. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risk factors include, but are not limited to, whether or when the Companies are able to gain FDA approval of the Acurox(R) Tablets NDA; whether additional clinical studies will be required to support FDA approval of the Acurox(R) Tablets NDA; whether or when the Companies may gain FDA approval of product labeling for the proposed indication or for abuse deterrent features; and the benefits of Acurox(R) and the ability of Acurox(R) to deter abuse in actual practice. Other important factors that may cause actual results to differ materially from the forward-looking statements are discussed in the "Risk Factors" section and other sections of each of the Companies' Annual Reports on Form 10-K for the year ended December 31, 2008 and their respective Quarterly Reports on Form 10-Q for the quarter ended March 31, 2009, each of which is on file with the U.S. Securities and Exchange Commission.


'/>"/>
SOURCE King Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
2. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
3. SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
4. Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
5. Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System
6. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
7. Malaria Vaccine Developer, Sanaria Inc., Receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech
8. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
9. AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria
10. Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
11. Agennix Receives Fast Track Designation From FDA for Talactoferrin in Combination With Sunitinib for Renal Cell Carcinoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... May 26, 2015 For the ... Quality of Life Throughout Europe, the Middle ... Astellas Pharma EMEA is celebrating its 10 ... through the historic merger of Japanese pharmaceutical companies Yamanouchi ... committed to turning science into value for patients through ...
(Date:5/22/2015)... May 22, 2015  Research and Benchmarking firm, ... Medical Affairs Roundtable on Thursday, May ... virtual roundtable to discuss "Medical Affairs, Role in ... Practices, Medical Affairs Consortium provides Medical Affairs leaders ... key challenges they face. The consortium has developed ...
(Date:5/22/2015)... OAKS, Calif. , May 22, 2015 ... announced the Company has commenced termination of ... of brodalumab with AstraZeneca (LON:AZN, STO:AZN and ... IL-17 inhibitor, is in development for patients ... axial spondyloarthritis.  The decision was based on ...
Breaking Medicine Technology:Astellas Pharma EMEA Celebrates Its 10th Anniversary 2Astellas Pharma EMEA Celebrates Its 10th Anniversary 3Astellas Pharma EMEA Celebrates Its 10th Anniversary 4Best Practices Sixth Medical Affairs Consortium Roundtable to Focus on Health Economics & Outcomes Research 2Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5
... The Pittsburgh Life Sciences Greenhouse (PLSG), ... formation and business growth programs to the region,s ... President and Chief Executive Officer, John W. ... signing an agreement with Ortho-McNeil-Janssen Pharmaceuticals, a Johnson ...
... Pa. , June 22 TheraQuest Biosciences, Inc., a ... TheraQuest also announced the launch of its new corporate website at ... , ... a careful strategic review of our pipeline, we have realigned our ...
Cached Medicine Technology:The Pittsburgh Life Sciences Greenhouse Congratulates Diamyd Medical on Its Agreement with Ortho-McNeil-Janssen Pharmaceuticals to Develop Diabetes Therapy 2TheraQuest Unveils New Pain Management Product Pipeline 2TheraQuest Unveils New Pain Management Product Pipeline 3TheraQuest Unveils New Pain Management Product Pipeline 4TheraQuest Unveils New Pain Management Product Pipeline 5
(Date:5/26/2015)... May 26, 2015 Hexagon Geospatial is ... Defence and Space in a new content-sharing program that ... for use in the development of smart applications. ... this partnership combines optical satellite data from Airbus Defence ... tear down the walls between geospatial content, software and ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 i2i Systems, ... solutions for more than 15 years, has earned 2014 ... Committee for Quality Assurance (NCQA) for its flagship product ... are proud of the work we have done to ... grateful for the acknowledgement from NCQA once again,” said ...
(Date:5/26/2015)... 2015 Scientists at the University of ... help advanced mesothelioma patients benefit from immunotherapy; surgery may ... article on the new research. Click here to ... of thoracic surgery and pulmonology theorized that, because large ... system attack, immunotherapy drugs might work better if the ...
(Date:5/26/2015)... 2015 ProTrailer Network is a new ... Pro X . This Effect includes 30 all ... styled text. , ProTrailer Network allows users to ... can easily complement any form of media project. FCPX ... can make professional looking openers. , ProTrailer Network includes ...
(Date:5/26/2015)... 2015 Learning ZoneXpress is excited to ... Education Cards . These cards have been specifically designed ... simple, easy-to-read text, these new educational resources are extremely ... practical nutrition tips and suggestions to clients and provide ... , + MyPlate: Eat for a Healthy Baby Pregnancy ...
Breaking Medicine News(10 mins):Health News:Hexagon Geospatial and Airbus Defense Establish Partnership 2Health News:Hexagon Geospatial and Airbus Defense Establish Partnership 3Health News:i2iTracks Earns NCQA 2014 PCMH Prevalidation 2Health News:i2iTracks Earns NCQA 2014 PCMH Prevalidation 3Health News:Researchers Say Surgery May Restore Effectiveness of Immunotherapy for Mesothelioma, According to Surviving Mesothelioma 2Health News:Developers at Pixel Film Studios Release ProTrailer Network for Final Cut Pro X 2Health News:Learning ZoneXpress Introduces New Educational Resource for WIC, SNAP-Ed, and EFNEP 2
... a forewarning from severe periodontal disease than non-diabetic pregnant ... periodontology.// ,Researchers from the University of Iowa Colleges ... and 20 non-diabetic women in their 20-39th week of ... the control of diabetes. They found the diabetics flaunted ...
... men who eat up tomato products more than twice ... prostate cancer. Consuming cooked tomatoes was particularly beneficial, according ... sauce, ketchup and other tomato-based foods lowered the prostate ... ,Dr. Edward Giovannucci of Brigham and Women's Hospital and ...
... transplant patients contracted a dangerous parasitic disease from their ... women died, but only one recovered after antibiotic treatment.// ... Disease Control and Prevention turned up 26 bacterial infections ... in the United States. ,This shows that the ...
... medications than smokers, as the extra weight poses them ... the nation's principal cause of preventable deaths, the surgeon ... ,For a more precise look at the ... from two national health surveys to estimate inpatient and ...
... Getting cold out of doors condenses the blood and increases ... of University of Texas, it has been found that too ... - in Britain. He believes that cold temperatures alter the ... raises the risk of clotting and heart attack. ...
... gender were among the best indicators of how you might ... state-by-state study of prescription drug use, where you live also ... you use. // ,According to the study, the percentage ... ranged from a high of 71 percent in Kansas to ...
Cached Medicine News:Health News:Prescription Drug Use Varies Widely Between States 2
Part of the Octopus System which includes both the Starfish & Octopus3. The Octopus3 Tissue Stabilizer is the pioneering and market-leading suction device....
... way to lift the heart - Guidant's ... 3. The XPOSE 3 is designed to ... surgery and to easily position and access ... both apical and non-apical placement on the ...
... The CLEARGLIDE Optical Vessel Dissector has application ... operative cavity in the extraperitoneal spaces such ... The device may be used in surgical ... EVH system enables harvesting of a quality ...
The MicroMed DeBakey VAD is a miniaturized heart pump designed to provide increased blood flow (up to 10L/min) from the left ventricle of the heart throughout the body for patients in end stage heart...
Medicine Products: